8-K: Arvinas ARV-102 Shows Positive Phase 1 Data for Parkinson's

Arvinas, Inc. announced positive Phase 1 clinical trial data for its PROTAC LRRK2 degrader, ARV-102, demonstrating safety, brain penetration, and target engagement in healthy volunteers and Parkinson's patients.

Summary

• Presented late-breaking, positive Phase 1 clinical trial data for ARV-102, a PROTAC LRRK2 degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders.
• Data from two trials were presented: ARV-102-101 (first-in-human in healthy volunteers) and ARV-102-103 (in patients with Parkinson's disease).
• ARV-102 was generally well tolerated at single doses up to 200 mg and multiple daily doses up to 80 mg in healthy volunteers, with no discontinuations due to adverse events (AEs) or serious adverse events (SAEs).
• In Parkinson's patients, single doses of 50 mg or 200 mg were well tolerated, with only mild treatment-related AEs (headache, diarrhea, nausea) and no SAEs.
• Demonstrated dose-dependent exposure in both plasma and cerebrospinal fluid (CSF) in both healthy volunteers and Parkinson's patients, indicating brain penetration.
• Achieved significant LRRK2 protein reductions: >90% in peripheral blood mononuclear cells (PBMCs) and >50% in CSF in healthy volunteers with repeated daily doses ≥20 mg.
• In Parkinson's patients, median PBMC LRRK2 protein reductions were 86% with the 50 mg dose and 97% with the 200 mg dose.
• Showed modulation of lysosomal and neuroinflammatory microglial pathways, with significant decreases in relevant CSF markers in healthy volunteers treated with 80 mg once daily for 14 days.
• Plans to present initial data from a multiple dose cohort of the Phase 1 trial in Parkinson's patients (ARV-102-103) in 2026.
• Intends to initiate a Phase 1b clinical trial of ARV-102 in patients with progressive supranuclear palsy in the first half of 2026, pending data and investigational new drug (IND) clearance.

Sentiment

Score: 9

Explanation: The filing reports overwhelmingly positive Phase 1 clinical trial data for ARV-102, demonstrating strong safety, excellent brain penetration, robust target degradation, and significant modulation of disease-relevant biomarkers. The results support accelerated development and expansion into new indications, indicating a highly favorable outlook for the drug candidate.

Positives

• ARV-102 was generally well tolerated in both healthy volunteers and Parkinson's patients, with no serious adverse events (SAEs) reported in either study.
• Demonstrated dose-dependent brain penetration, evidenced by ARV-102 exposure increasing in cerebrospinal fluid (CSF).
• Achieved significant target engagement, with >90% LRRK2 protein reduction in PBMCs and >50% in CSF in healthy volunteers with repeated daily doses ≥20 mg.
• Showed robust LRRK2 protein degradation in Parkinson's patients, with median PBMC LRRK2 reductions of 86% (50 mg dose) and 97% (200 mg dose).
• Positive biomarker data indicated modulation of disease-relevant pathways, including reduced plasma phospho-Rab10T73, urine bis(monoacylglycerol)phosphate (BMP), and significant decreases in lysosomal and neuroinflammatory microglial markers in CSF.
• The CSF proteomics data in healthy volunteers showed effects on distal pathway biomarkers known to be elevated in LRRK2 Parkinson's disease, which is a significant finding for an investigational LRRK2 therapy at 14 days.
• The positive data supports intensified development of ARV-102 in Parkinson's disease and future studies in progressive supranuclear palsy.

Negatives

• Mild treatment-related adverse events, including headache, diarrhea, and nausea, were observed in Parkinson's patients.

Risks

• Actual results or events could differ materially from plans, intentions, or expectations.
• Uncertainty regarding the successful conduct and completion of development for product candidates, including ARV-102, on current timelines or at all.
• Risks related to clinical trial results and their interpretation.
• Ability to protect intellectual property portfolio.
• Reliance on third parties.
• Ability to raise capital when needed.
• Sufficiency of cash and cash equivalents to fund foreseeable and unforeseeable operating expenses and capital expenditure requirements.

Future Outlook

The company believes the positive Phase 1 data for ARV-102 supports intensified development in ongoing studies for Parkinson's disease and future studies for progressive supranuclear palsy. Plans include presenting initial data from a multiple dose cohort of the Parkinson's disease trial (ARV-102-103) in 2026 and initiating a Phase 1b trial for progressive supranuclear palsy in the first half of 2026, contingent on further data and investigational new drug clearance.

Management Comments

• "We are particularly excited by the CSF proteomics results, which demonstrate modulation of lysosomal and microglial pathways that are known to be associated with neurodegenerative diseases. We believe these findings support the intensified development of ARV-102 in ongoing studies of patients with Parkinsons disease, and in future studies of patients with progressive supranuclear palsy." Noah Berkowitz, M.D., Ph.D., Chief Medical Officer of Arvinas.
• "To our knowledge, this is the first time an investigational LRRK2 therapy has, at 14 days in healthy volunteers, shown effects on distal pathway biomarkers in CSF that are elevated in patients with LRRK2 Parkinsons disease. These data highlight the potential of PROTACmediated LRRK2 degradation, encouraging further development that could benefit patients in the future." John Houston, Ph.D., Chairperson, Chief Executive Officer, and President at Arvinas.

Industry Context

This announcement positions Arvinas as a leader in the targeted protein degradation (PROTAC) space, specifically for neurodegenerative diseases. LRRK2 is a well-established target for Parkinson's disease, with mutations being a frequent familial cause and variants linked to idiopathic Parkinson's and progressive supranuclear palsy. The demonstration of brain penetration and significant LRRK2 degradation, coupled with positive biomarker modulation, suggests ARV-102 could be a significant advancement in a field with high unmet medical need. The ability to modulate lysosomal and neuroinflammatory microglial pathways, which are associated with neurodegeneration, is particularly noteworthy and aligns with current research trends focusing on broader disease mechanisms beyond symptomatic treatment.

Comparison to Industry Standards

• The company states that, to its knowledge, ARV-102 is the first investigational LRRK2 therapy to show effects on distal pathway biomarkers in CSF, which are elevated in patients with LRRK2 Parkinson's disease, within 14 days in healthy volunteers. This suggests a potentially differentiated profile compared to other LRRK2 inhibitors or degraders in earlier stages of development.
• While specific comparable companies or projects are not named in the filing, the LRRK2 inhibition space has seen activity from companies like Denali Therapeutics (with DNL201 and DNL151, which are LRRK2 inhibitors, not degraders) and Roche. Arvinas's PROTAC approach aims for degradation rather than inhibition, which could offer advantages in sustained target knockdown and potentially different safety/efficacy profiles. The robust LRRK2 protein reduction (86-97% in PBMCs) and CSF biomarker modulation are strong indicators of target engagement and pathway impact, which would be assessed against similar metrics from other LRRK2-targeting programs.

Stakeholder Impact

• Shareholders: Positive clinical data for a key pipeline asset (ARV-102) is likely to increase investor confidence and potentially lead to an appreciation in share price. The progression to further trials and new indications expands the drug's market potential.
• Patients with Parkinson's Disease: The positive safety and efficacy signals, particularly the robust LRRK2 degradation and biomarker modulation, offer hope for a new, potentially disease-modifying treatment option.
• Patients with Progressive Supranuclear Palsy: The intention to initiate a Phase 1b trial for PSP opens a new therapeutic avenue for a severe, currently untreatable neurodegenerative disorder.
• Employees: Positive clinical trial results can boost morale, validate research efforts, and potentially lead to increased investment in the company's R&D programs.
• Regulatory Authorities: The positive Phase 1 data will be crucial for future regulatory submissions and discussions regarding ARV-102's development path.

Next Steps

• Present initial data from a multiple dose cohort of the Phase 1 clinical trial of ARV-102 in patients with Parkinson's disease (ARV-102-103) in 2026.
• Initiate a Phase 1b clinical trial of ARV-102 in patients with progressive supranuclear palsy in the first half of 2026, pending data from the multiple dose cohort and investigational new drug clearance.
• Continue intensified development of ARV-102 in ongoing studies of patients with Parkinson's disease.

Key Dates

Recommendation

The reported Phase 1 data for ARV-102 is exceptionally strong, demonstrating a favorable safety profile, clear brain penetration, and highly effective target engagement (LRRK2 degradation) in both healthy volunteers and Parkinson's patients. Crucially, the drug showed significant modulation of lysosomal and neuroinflammatory biomarkers in CSF, indicating a potential disease-modifying effect. The company's plans for accelerated development in Parkinson's and expansion into progressive supranuclear palsy further enhance the drug's market potential. These positive early-stage results significantly de-risk the asset and suggest a high probability of success in later-stage trials, making Arvinas a compelling investment opportunity.

Keywords

ARV-102, Parkinson's Disease, PROTAC, LRRK2 Degrader, Neurodegenerative Disorders, Clinical Trial, Phase 1, Biotechnology, Arvinas, Progressive Supranuclear Palsy, Protein Degradation